Jayson Bedford
Stock Analyst at Raymond James
(3.88)
# 625
Out of 4,910 analysts
313
Total ratings
56.08%
Success rate
7.29%
Average return
Main Sectors:
Stocks Rated by Jayson Bedford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Outperform | $142 → $141 | $125.73 | +12.15% | 29 | Jul 18, 2025 | |
| PODD Insulet | Maintains: Outperform | $328 → $360 | $285.57 | +26.06% | 27 | May 27, 2025 | |
| ICUI ICU Medical | Maintains: Strong Buy | $197 → $187 | $126.41 | +47.94% | 20 | May 9, 2025 | |
| MASI Masimo | Maintains: Outperform | $204 → $185 | $158.23 | +16.92% | 7 | May 7, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $119 → $104 | $96.52 | +7.75% | 8 | May 6, 2025 | |
| MMSI Merit Medical Systems | Maintains: Outperform | $116 → $108 | $84.46 | +27.87% | 27 | Apr 25, 2025 | |
| BSX Boston Scientific | Maintains: Strong Buy | $122 → $121 | $103.16 | +17.29% | 25 | Apr 24, 2025 | |
| JNJ Johnson & Johnson | Maintains: Outperform | $162 → $164 | $167.93 | -2.34% | 23 | Apr 16, 2025 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $560 → $688 | $511.00 | +34.64% | 8 | Jan 24, 2025 | |
| DXCM DexCom | Maintains: Strong Buy | $115 → $99 | $85.12 | +16.31% | 30 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $275 → $270 | $181.28 | +48.94% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $12.54 | +3.67% | 1 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $10 | $9.13 | +9.53% | 14 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $227 → $271 | $115.20 | +135.24% | 12 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.10 | - | 10 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $15.31 | - | 13 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $76.30 | - | 20 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $27.51 | - | 6 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $91.65 | - | 14 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $0.58 | - | 4 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $86 | $65.37 | +31.56% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.27 | - | 5 | Aug 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.05 | - | 3 | Jan 2, 2018 |
Abbott Laboratories
Jul 18, 2025
Maintains: Outperform
Price Target: $142 → $141
Current: $125.73
Upside: +12.15%
Insulet
May 27, 2025
Maintains: Outperform
Price Target: $328 → $360
Current: $285.57
Upside: +26.06%
ICU Medical
May 9, 2025
Maintains: Strong Buy
Price Target: $197 → $187
Current: $126.41
Upside: +47.94%
Masimo
May 7, 2025
Maintains: Outperform
Price Target: $204 → $185
Current: $158.23
Upside: +16.92%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Outperform
Price Target: $119 → $104
Current: $96.52
Upside: +7.75%
Merit Medical Systems
Apr 25, 2025
Maintains: Outperform
Price Target: $116 → $108
Current: $84.46
Upside: +27.87%
Boston Scientific
Apr 24, 2025
Maintains: Strong Buy
Price Target: $122 → $121
Current: $103.16
Upside: +17.29%
Johnson & Johnson
Apr 16, 2025
Maintains: Outperform
Price Target: $162 → $164
Current: $167.93
Upside: -2.34%
Intuitive Surgical
Jan 24, 2025
Maintains: Outperform
Price Target: $560 → $688
Current: $511.00
Upside: +34.64%
DexCom
Oct 25, 2024
Maintains: Strong Buy
Price Target: $115 → $99
Current: $85.12
Upside: +16.31%
Aug 2, 2024
Maintains: Outperform
Price Target: $275 → $270
Current: $181.28
Upside: +48.94%
Jul 1, 2024
Initiates: Outperform
Price Target: $13
Current: $12.54
Upside: +3.67%
Jan 9, 2024
Maintains: Outperform
Price Target: $12 → $10
Current: $9.13
Upside: +9.53%
Dec 20, 2023
Maintains: Outperform
Price Target: $227 → $271
Current: $115.20
Upside: +135.24%
Nov 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $12.10
Upside: -
Apr 24, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $15.31
Upside: -
Feb 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $76.30
Upside: -
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $27.51
Upside: -
Aug 24, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $91.65
Upside: -
Mar 5, 2021
Downgrades: Underperform
Price Target: n/a
Current: $0.58
Upside: -
Nov 5, 2020
Maintains: Outperform
Price Target: $75 → $86
Current: $65.37
Upside: +31.56%
Aug 2, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.27
Upside: -
Jan 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $12.05
Upside: -